BRVE
Braveheart Bio, Inc. Common Stock
Nasdaq · usd
Braveheart Bio, Inc. Common Stock (BRVE) trades at $18.00 (-4.15%) as of 4:29:23 PM EST on Nov 18, 2026, -8.58% over the past month. Market cap is $1.67B, with 19.6 days to cover in short interest.
Stock performance
How Braveheart Bio, Inc. Common Stock (BRVE) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.33%
- 1W
- -11.34%
- 1M
- -8.58%
- YTD
- -37.82%
- 1Y
- -37.82%
- 52-wk range
- $16.70 – $32.00
Key statistics
Today's trading snapshot for BRVE: day range, open, previous close, volume and market cap.
- Day range
- $17.94 – $19.46
- Open
- $18.75
- Prev close
- $18.78
- Volume
- 706.91K
- Market cap
- $1.67B
- Shares out
- 90.04M
8-K filings
Material corporate events Braveheart Bio, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 10, 2026
On November 10, 2026, Braveheart Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.
- Clinical trial resultsNov 6, 2026
On November 6, 2026, Braveheart Bio, Inc. issued a press release titled “Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026.”
- Quarterly earningsSep 8, 2026
On September 8, 2026, Braveheart Bio, Inc. (the "Company") announced its financial results and business highlights for the quarter ended June 30, 2026.
- Charter amendmentAug 7, 2026
The Company filed its second amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on August 7, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.
BRVE short interest
How heavily BRVE is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 19.6
- Short interest
- 5.15M
- Avg volume
- 262.57K
As of · reported to FINRA twice monthly.
BRVE news
The latest news and headlines about Braveheart Bio, Inc. Common Stock (BRVE).
- Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?positiveThe Motley Fool· Aug 10, 2026
Frequently asked questions
What is the Braveheart Bio, Inc. Common Stock (BRVE) stock price today?
Braveheart Bio, Inc. Common Stock (BRVE) is trading at $18.00 (-4.15% on the day) as of 4:29:23 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Braveheart Bio, Inc. Common Stock?
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases.
What is the short interest in BRVE?
As of Oct 30, 2026, BRVE has 5.15M shares short and 19.6 days to cover.
What exchange is BRVE listed on?
Braveheart Bio, Inc. Common Stock (BRVE) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of BRVE with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BRVE analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.